No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
orelabrutinib Sensitive: A1 - Approval
|
orelabrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
lenalidomide Sensitive: A1 - Approval
|
lenalidomide Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
temsirolimus Sensitive: A1 - Approval
|
temsirolimus Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
rituximab + bortezomib Sensitive: A1 - Approval
|
rituximab + bortezomib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
bortezomib Sensitive: A1 - Approval
|
bortezomib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
avapritinib Sensitive: A1 - Approval
|
avapritinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
venetoclax + ibrutinib Sensitive: A2 - Guideline
|
venetoclax + ibrutinib Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
bendamustine Sensitive: A2 - Guideline
|
bendamustine Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib + lenalidomide Sensitive: A2 - Guideline
|
rituximab + ibrutinib + lenalidomide Sensitive: A2 - Guideline
|
ALK negative
|
Mantle Cell Lymphoma
|
ALK negative
|
Mantle Cell Lymphoma
|
brentuximab vedotin Sensitive: A2 - Guideline
|
brentuximab vedotin Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
VR-CAP Sensitive: A2 - Guideline
|
VR-CAP Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
R-DHAP Sensitive: A2 - Guideline
|
R-DHAP Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
R-DHAX Sensitive: A2 - Guideline
|
R-DHAX Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
R-CVAD Sensitive: A2 - Guideline
|
R-CVAD Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
R-GemOx Sensitive: A2 - Guideline
|
R-GemOx Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
venetoclax + rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib Sensitive: A2 - Guideline
|
rituximab + ibrutinib Sensitive: A2 - Guideline
|
CCR7 positive
|
Mantle Cell Lymphoma
|
CCR7 positive
|
Mantle Cell Lymphoma
|
brexucabtagene autoleucel Sensitive: B - Late Trials
|
brexucabtagene autoleucel Sensitive: B - Late Trials
|
ABCB1 mutation + VEGFA mutation
|
Mantle Cell Lymphoma
|
ABCB1 mutation + VEGFA mutation
|
Mantle Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
VEGFA mutation
|
Mantle Cell Lymphoma
|
VEGFA mutation
|
Mantle Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
ABCB1 mutation
|
Mantle Cell Lymphoma
|
ABCB1 mutation
|
Mantle Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
INCB50465 Sensitive: B - Late Trials
|
INCB50465 Sensitive: B - Late Trials
|
CCND1 overexpression
|
Mantle Cell Lymphoma
|
CCND1 overexpression
|
Mantle Cell Lymphoma
|
INCB50465 Sensitive: C2 – Inclusion Criteria
|
INCB50465 Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib Sensitive: C2 – Inclusion Criteria
|
rituximab + ibrutinib Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
venetoclax + obinutuzumab + zanubrutinib Sensitive: C2 – Inclusion Criteria
|
venetoclax + obinutuzumab + zanubrutinib Sensitive: C2 – Inclusion Criteria
|
NLRC5 mutation
|
Mantle Cell Lymphoma
|
NLRC5 mutation
|
Mantle Cell Lymphoma
|
acalabrutinib Resistant: C3 – Early Trials
|
acalabrutinib Resistant: C3 – Early Trials
|
B2M mutation
|
Mantle Cell Lymphoma
|
B2M mutation
|
Mantle Cell Lymphoma
|
acalabrutinib Resistant: C3 – Early Trials
|
acalabrutinib Resistant: C3 – Early Trials
|
CARD11 mutation
|
Mantle Cell Lymphoma
|
CARD11 mutation
|
Mantle Cell Lymphoma
|
acalabrutinib Resistant: C3 – Early Trials
|
acalabrutinib Resistant: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib + lenalidomide Sensitive: C3 – Early Trials
|
rituximab + ibrutinib + lenalidomide Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Mantle Cell Lymphoma
|
PD-L1 underexpression
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
CDKN2A deletion
|
Mantle Cell Lymphoma
|
CDKN2A deletion
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
Immunotherapy + lenalidomide Resistant: C3 – Early Trials
|
Immunotherapy + lenalidomide Resistant: C3 – Early Trials
|
ATM mutation
|
Mantle Cell Lymphoma
|
ATM mutation
|
Mantle Cell Lymphoma
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + ibrutinib Sensitive: C3 – Early Trials
|
PRMT5 overexpression + MTAP deletion
|
Mantle Cell Lymphoma
|
PRMT5 overexpression + MTAP deletion
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
CDKN2A deletion + MTAP deletion
|
Mantle Cell Lymphoma
|
CDKN2A deletion + MTAP deletion
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
HES1 overexpression
|
Mantle Cell Lymphoma
|
HES1 overexpression
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
SOX11 expression
|
Mantle Cell Lymphoma
|
SOX11 expression
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
CTLA4 overexpression
|
Mantle Cell Lymphoma
|
CTLA4 overexpression
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
ITK overexpression
|
Mantle Cell Lymphoma
|
ITK overexpression
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
|
R-CHOP Resistant: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
NOTCH1 mutation
|
Mantle Cell Lymphoma
|
NOTCH1 mutation
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
ARID1B deletion
|
Mantle Cell Lymphoma
|
ARID1B deletion
|
Mantle Cell Lymphoma
|
temsirolimus Resistant: C3 – Early Trials
|
temsirolimus Resistant: C3 – Early Trials
|
DLGAP2 deletion
|
Mantle Cell Lymphoma
|
DLGAP2 deletion
|
Mantle Cell Lymphoma
|
temsirolimus Resistant: C3 – Early Trials
|
temsirolimus Resistant: C3 – Early Trials
|
BIRC3 mutation
|
Mantle Cell Lymphoma
|
BIRC3 mutation
|
Mantle Cell Lymphoma
|
temsirolimus Resistant: C3 – Early Trials
|
temsirolimus Resistant: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
rituximab + lenalidomide Sensitive: C3 – Early Trials
|
rituximab + lenalidomide Sensitive: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
venetoclax + rituximab + lenalidomide Sensitive: C3 – Early Trials
|
venetoclax + rituximab + lenalidomide Sensitive: C3 – Early Trials
|
CD20 positive
|
Mantle Cell Lymphoma
|
CD20 positive
|
Mantle Cell Lymphoma
|
GEN3013 Sensitive: C3 – Early Trials
|
GEN3013 Sensitive: C3 – Early Trials
|
TP53 overexpression
|
Mantle Cell Lymphoma
|
TP53 overexpression
|
Mantle Cell Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
Chr t(11;14)
|
Mantle Cell Lymphoma
|
Chr t(11;14)
|
Mantle Cell Lymphoma
|
INCB50465 Sensitive: C3 – Early Trials
|
INCB50465 Sensitive: C3 – Early Trials
|
TP53 deletion
|
Mantle Cell Lymphoma
|
TP53 deletion
|
Mantle Cell Lymphoma
|
venetoclax + rituximab + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + rituximab + ibrutinib Sensitive: C3 – Early Trials
|
TP53 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation
|
Mantle Cell Lymphoma
|
venetoclax + rituximab + ibrutinib Sensitive: C3 – Early Trials
|
venetoclax + rituximab + ibrutinib Sensitive: C3 – Early Trials
|
TP53 mutation + CARD11 mutation + SMARCA4 mutation
|
Mantle Cell Lymphoma
|
TP53 mutation + CARD11 mutation + SMARCA4 mutation
|
Mantle Cell Lymphoma
|
venetoclax + obinutuzumab + zanubrutinib Sensitive: C4 – Case Studies
|
venetoclax + obinutuzumab + zanubrutinib Sensitive: C4 – Case Studies
|
PIK3CD expression
|
Mantle Cell Lymphoma
|
PIK3CD expression
|
Mantle Cell Lymphoma
|
BI 6727 Sensitive: D – Preclinical
|
BI 6727 Sensitive: D – Preclinical
|
ROR1 expression
|
Mantle Cell Lymphoma
|
ROR1 expression
|
Mantle Cell Lymphoma
|
MK-2140 Sensitive: D – Preclinical
|
MK-2140 Sensitive: D – Preclinical
|
MYC overexpression
|
Mantle Cell Lymphoma
|
MYC overexpression
|
Mantle Cell Lymphoma
|
TG-1701 Sensitive: D – Preclinical
|
TG-1701 Sensitive: D – Preclinical
|
IL6 elevation
|
Mantle Cell Lymphoma
|
IL6 elevation
|
Mantle Cell Lymphoma
|
TG-1701 Sensitive: D – Preclinical
|
TG-1701 Sensitive: D – Preclinical
|
IL2 elevation
|
Mantle Cell Lymphoma
|
IL2 elevation
|
Mantle Cell Lymphoma
|
TG-1701 Sensitive: D – Preclinical
|
TG-1701 Sensitive: D – Preclinical
|
IL2 elevation
|
Mantle Cell Lymphoma
|
IL2 elevation
|
Mantle Cell Lymphoma
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|
IL6 elevation
|
Mantle Cell Lymphoma
|
IL6 elevation
|
Mantle Cell Lymphoma
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|
TNFA elevation
|
Mantle Cell Lymphoma
|
TNFA elevation
|
Mantle Cell Lymphoma
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|
umbralisib + TG-1701 + ublituximab Sensitive: D – Preclinical
|
LY9 expression
|
Mantle Cell Lymphoma
|
LY9 expression
|
Mantle Cell Lymphoma
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|
BTK C481S
|
Mantle Cell Lymphoma
|
BTK C481S
|
Mantle Cell Lymphoma
|
TG-1701 Sensitive: D – Preclinical
|
TG-1701 Sensitive: D – Preclinical
|
PIK3CG expression
|
Mantle Cell Lymphoma
|
PIK3CG expression
|
Mantle Cell Lymphoma
|
copanlisib Sensitive: D – Preclinical
|
copanlisib Sensitive: D – Preclinical
|
PIK3CG expression
|
Mantle Cell Lymphoma
|
PIK3CG expression
|
Mantle Cell Lymphoma
|
BI 6727 Sensitive: D – Preclinical
|
BI 6727 Sensitive: D – Preclinical
|
PIK3CG expression
|
Mantle Cell Lymphoma
|
PIK3CG expression
|
Mantle Cell Lymphoma
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
PIK3CD expression
|
Mantle Cell Lymphoma
|
PIK3CD expression
|
Mantle Cell Lymphoma
|
copanlisib Sensitive: D – Preclinical
|
copanlisib Sensitive: D – Preclinical
|
PIK3CD expression
|
Mantle Cell Lymphoma
|
PIK3CD expression
|
Mantle Cell Lymphoma
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
PIK3CB expression
|
Mantle Cell Lymphoma
|
PIK3CB expression
|
Mantle Cell Lymphoma
|
copanlisib Sensitive: D – Preclinical
|
copanlisib Sensitive: D – Preclinical
|
PIK3CB expression
|
Mantle Cell Lymphoma
|
PIK3CB expression
|
Mantle Cell Lymphoma
|
BI 6727 Sensitive: D – Preclinical
|
BI 6727 Sensitive: D – Preclinical
|
PIK3CB expression
|
Mantle Cell Lymphoma
|
PIK3CB expression
|
Mantle Cell Lymphoma
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
PIK3CA expression
|
Mantle Cell Lymphoma
|
PIK3CA expression
|
Mantle Cell Lymphoma
|
copanlisib Sensitive: D – Preclinical
|
copanlisib Sensitive: D – Preclinical
|
PIK3CA expression
|
Mantle Cell Lymphoma
|
PIK3CA expression
|
Mantle Cell Lymphoma
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
copanlisib + BI 6727 Sensitive: D – Preclinical
|
PIK3CA expression
|
Mantle Cell Lymphoma
|
PIK3CA expression
|
Mantle Cell Lymphoma
|
BI 6727 Sensitive: D – Preclinical
|
BI 6727 Sensitive: D – Preclinical
|
BCL2L1 overexpression
|
Mantle Cell Lymphoma
|
BCL2L1 overexpression
|
Mantle Cell Lymphoma
|
venetoclax Resistant: D – Preclinical
|
venetoclax Resistant: D – Preclinical
|
SYK overexpression
|
Mantle Cell Lymphoma
|
SYK overexpression
|
Mantle Cell Lymphoma
|
piceatannol Sensitive: D – Preclinical
|
piceatannol Sensitive: D – Preclinical
|
TP53 deletion
|
Mantle Cell Lymphoma
|
TP53 deletion
|
Mantle Cell Lymphoma
|
venetoclax Resistant: D – Preclinical
|
venetoclax Resistant: D – Preclinical
|
CCND1 expression
|
Mantle Cell Lymphoma
|
CCND1 expression
|
Mantle Cell Lymphoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
ATM underexpression
|
Mantle Cell Lymphoma
|
ATM underexpression
|
Mantle Cell Lymphoma
|
olaparib Sensitive: D – Preclinical
|
olaparib Sensitive: D – Preclinical
|
CCND1 expression + CDK4 expression
|
Mantle Cell Lymphoma
|
CCND1 expression + CDK4 expression
|
Mantle Cell Lymphoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
NOTCH1 mutation
|
Mantle Cell Lymphoma
|
NOTCH1 mutation
|
Mantle Cell Lymphoma
|
Compound E Sensitive: D – Preclinical
|
Compound E Sensitive: D – Preclinical
|
SAMHD1 mutation
|
Mantle Cell Lymphoma
|
SAMHD1 mutation
|
Mantle Cell Lymphoma
|
fludarabine IV Resistant: D – Preclinical
|
fludarabine IV Resistant: D – Preclinical
|
SAMHD1 mutation
|
Mantle Cell Lymphoma
|
SAMHD1 mutation
|
Mantle Cell Lymphoma
|
cytarabine Resistant: D – Preclinical
|
cytarabine Resistant: D – Preclinical
|